What it is
This stack combines BPC-157 with TB-500. BPC-157 is studied mainly in preclinical tissue and gastrointestinal models; TB-500 is a synthetic fragment related to thymosin beta-4 and is used in repair and cell-migration research. The compounds have different dose scales and exposure patterns, so keep them separate rather than treating them as interchangeable or as a fixed-ratio product.
Evidence boundary
Preclinical evidence dominates for BPC-157 and research use of TB-500. The combination has no validated human schedule.
Preparation and measurement
Reconstitution: 10 mg vial + 2 mL BAC = 5 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–2, BPC-157 loading | 500–750 mcg | Calculated from the BPC vial | Once daily | 3.5–5.25 mg/week |
| Weeks 3–4, BPC-157 maintenance | 250–500 mcg | Calculated from the BPC vial | Once daily | 1.75–3.5 mg/week |
| Weeks 1–4, TB-500 | 1–2.5 mg | Calculated from the TB-500 vial | Twice weekly | 2–5 mg/week |
Weeks 1–2, BPC-157 loading
- Dose
- 500–750 mcg
- Draw / measure
- Calculated from the BPC vial
- Frequency
- Once daily
- Weekly total
- 3.5–5.25 mg/week
Weeks 3–4, BPC-157 maintenance
- Dose
- 250–500 mcg
- Draw / measure
- Calculated from the BPC vial
- Frequency
- Once daily
- Weekly total
- 1.75–3.5 mg/week
Weeks 1–4, TB-500
- Dose
- 1–2.5 mg
- Draw / measure
- Calculated from the TB-500 vial
- Frequency
- Twice weekly
- Weekly total
- 2–5 mg/week
Weekly totals apply only during the active phase.
Titration rules
- BPC-157 uses a higher daily loading range for the first two weeks, then a lower maintenance range.
- TB-500 is split across two weekly administrations; do not turn the weekly total into a daily dose.
- No clinical trial validates the stack as a combined protocol.
Cycle length and breaks
Use a defined 4-week active block, then reassess.
What to monitor
- Pain and swelling
- Range of motion and task-specific function
- Injection-site reactions
- Whether symptoms are improving without forcing automatic dose escalation
Practical rules
- Keep timing, route, concentration, and observation notes consistent if you are comparing notes.
- Do not merge the two ingredients into a fixed ratio dose claim.
- Record total exposure and per-component exposure separately.
Related protocols
BPC-157 Peptide Protocol & DosingTB-500 (Thymosin Beta-4) Protocol & DosingGHK-Cu Peptide Protocol & Dosing Supply & lot verification
Availability and batch-linked COA records for BPC-157 + TB-500 Peptide Stack & Dosing are kept with the current product listing.
View availability & COA → Verification notes